1. Novavax Expands Coronavirus Vaccine Manufacturing Deal in India  Nasdaq
  2. Serum Institute Of India To Resume Clinical Trial Of Oxford Covid-19 Vaccine  India Today
  3. It Will Take Until 2024 for Everyone to Get a COVID-19 Vaccine. Why So Long?  Popular Mechanics
  4. COVID-19: Why India should take lead on vaccine delivery  Gulf News
  5. India Should Take the Lead on Vaccine Delivery  Bloomberg
  6. View Full coverage on Google News

It could take years to widely distribute the COVID-19 (coronavirus) vaccine, experts say. Why so long?The world could be waiting a while.

COVID-19 Vaccine: When Will Everyone in the World Get a Vaccine?

Chief executive officer at the Serum Institute of India, Adar Poonawalla, told the Financial Times companies don't have capacity to make enough doses for the entire world before 2024.Chief executive officer at the Serum Institute of India, Adar Poonawalla, told the Financial Times companies don't have capacity to make enough doses for the entire world before 2024.

Companies 'will take four YEARS' to manufacture enough coronavirus vaccine for the world | Daily Mail Online

Bloomberg - Are you a robot?

One big challenge to immunise everyone will be the storage and transportation of vaccineOne big challenge to immunise everyone will be the storage and transportation of vaccine

COVID-19: Why India should take lead on vaccine delivery | Op-eds – Gulf News

If vaccine delivery mechanism can be evolved in India, other developing countries can replicate it. Without one, they can’t escape pandemic even with vaccine.If vaccine delivery mechanism can be evolved in India, other developing countries can replicate it. Without one, they can’t escape pandemic even with vaccine.

Why India needs to be a model to the world on Covid vaccine delivery

If vaccine delivery mechanism can be evolved in India, other developing countries can replicate it. Without one, they can’t escape pandemic even with vaccine.If vaccine delivery mechanism can be evolved in India, other developing countries can replicate it. Without one, they can’t escape pandemic even with vaccine.

Why India needs to be a model to the world on Covid vaccine delivery

Hindustan TimesDirector General of the Indian Council of Medical Research (ICMR), Dr Balram Bhargava said three vaccine candidates are at different clinical trial stages in India. Covid-19 vaccine candidates being manufactured by Cadila Healthcare and Bharat Biotech have completed the first phase of the trial while the Serum Institute of India (SII) will begin with Phase 3 trial after getting the nod, Balram Bhargava, ICMR’s director general, said during the health ministry’s briefing.The Pune-based Serum Institute will conduct the Phase 3 trial on 1,500 volunteers across 14 locations, Bhargava added.Hindustan TimesDirector General of the Indian Council of Medical Research (ICMR), Dr Balram Bhargava said three vaccine candidates are at different clinical trial stages in India. Covid-19 vaccine candidates being manufactured by Cadila Healthcare and Bharat Biotech have completed the first phase of the trial while the Serum Institute of India (SII) will begin with Phase 3 trial after getting the nod, Balram Bhargava, ICMR’s director general, said during the health ministry’s briefing.The Pune-based Serum Institute will conduct the Phase 3 trial on 1,500 volunteers across 14 locations, Bhargava added.

Covid: 3 vaccines at clinical trial stage in India; SII’s phase 3 trial soon - coronavirus-crisis - videos - Hindustan Times

Serum Institute of India has received Indian regulatory approval to resume local clinical trials of AstraZeneca's potential COVID-19 vaccine, a source familiar with the matter said on Wednesday.Serum Institute of India has received Indian regulatory approval to resume local clinical trials of AstraZeneca's potential COVID-19 vaccine, a source familiar with the matter said on Wednesday.

Serum Institute gets approval to resume India trial of AstraZeneca COVID vaccine: source | Reuters

Novavax, Inc. (NASDAQ: NVAX), which has a Phase 2 study underway of its coronavirus vaccine candidate NVX-CoV2373, is diligently working on partnerships to ...Novavax, Inc. (NASDAQ: NVAX), which has a Phase 2 study underway of its coronavirus vaccine candidate NVX-CoV2373, is diligently working on partnerships to boost its...

Novavax, Inc. (NASDAQ:NVAX) - Novavax Expands Coronavirus Vaccine Capacity To More Than 2B Doses In 2021 | Benzinga

An expanded arrangement with a local producer should allow for 2 billion doses to be manufactured annually.An expanded arrangement with a local producer should allow for 2 billion doses to be manufactured annually.

Novavax Doubling Coronavirus Vaccine Production Capacity With Expanded India Deal | The Motley Fool

In August, Novavax signed a deal with Serum Institute, the world's largest producer of vaccines, to produce a minimum of one billion doses of its vaccine candidate, when approved, for low- and middle-income countries and India. As part of the expanded agreement, Serum Institute will also manufactureIn August, Novavax signed a deal with Serum Institute, the world's largest producer of vaccines, to produce a minimum of one billion doses of its vaccine candidate, when approved, for low- and middle-income countries and India. As part of the expanded agreement, Serum Institute will also manufacture

Novavax aims for 2 billion COVID-19 vaccine doses with expanded India deal

When told that vaccine developments are taking place at good pace globally and doses will likely become available to the public in six months, do I hear that I will get a dose in six...When told that vaccine developments are taking place at good pace globally and doses will likely become available to the public in six months, do I hear that I will get a dose in six...

Poonawalla sounds an alarm: What it will take to vaccinate India against Covid

Access to this page has been denied.

Serum Institute of India will also focus on producing the antigen component of the potential vaccine of Novavax, which is being called NVX-CoV2373.Serum Institute of India will also focus on producing the antigen component of the potential vaccine of Novavax, which is being called NVX-CoV2373.

Coronavirus vaccine update: Serum Institute of India and Novavax join hands to produce two billion doses of COVID vaccine | The Times of India

The DCGI has, however, put certain conditions like taking extra care during screening, providing additional information in informed consent and close monitoring for adverse events during follow-up of the study

Serum Institute receives DCGI approval to resume trials of Oxford COVID-19 vaccine - Express Pharma

Despite a lackluster history of taking vaccines to market, Maryland's Novavax is streaking through clinical trials for its promising COVID-19 shot candidate. Going commercial is a whole other beast, however, and Novavax is now expanding one of its key manufacturing deals to aid the cause. Despite a lackluster history of taking vaccines to market, Maryland's Novavax is streaking through clinical trials for its promising COVID-19 shot candidate. Going commercial is a whole other beast, however, and Novavax is now expanding one of its key manufacturing deals to aid the cause. 

Novavax adds antigens to COVID-19 production pact with Indian vaccines giant | FiercePharma

New Delhi, September 16 Drugs Controller General of India (DCGI) Dr V G Somani has gave permission to Serum Institute of India to resume clinical trial of the Oxford COVID-19 vaccine candidate in theOn September 11, phase two and three clinical trial were suspended after " unexplained illness" in a participant Drugs Controller General of India (DCGI) Dr V G Somani has gave permission to Serum Institute of India to resume clinical trial of the Oxford COVID-19 vaccine candidate in the country while revoking its earlier order of suspending any new recruitment for phase two and three trial.

Serum Institute gets nod to resume Oxford Covid vaccine trials in India : The Tribune India

Prime Minister Narendra Modi announced in his Independence Day speech: India has 3 vaccines. Pune-based Serum Institute of India was the first to produce aPrime Minister Narendra Modi announced in his Independence Day speech: India has 3 vaccines. Pune-based Serum Institute of India was the first to produce a

Coronavirus Vaccine: SII Will Start Phase III Trials In Mid-October! Will India Get The COVID-19 Vaccine By December 2020? | Inventiva

A day after Union Health minster Harsh Vardhan assured about the development of a vaccine against the novel coronavirus early next year, Serum Vaccine of India chief executive Adar Poonawalla clarifies,"It’s going to take four to five years until everyone gets the vaccine on this planet", as told to the Financial Times.  Get latest Healthcare online at cnbctv18.com A day after Union Health minster Harsh Vardhan assured about the development of a vaccine against the novel coronavirus early next year, Serum Vaccine of India chief executive Adar Poonawalla clarifies,"It’s going to take four to five years until everyone gets the vaccine on this planet",

Serum Institute CEO warns 'COVID vaccine won't be available to all before 2024-end' - cnbctv18.com

COVID-19 vaccine candidates being developed by Cadila Healthcare and Bharat Biotech have completed the phase one of the study while Pune-based Serum Institute of India (SII) will begin with Phase 3 clinical trial after getting regulatory nod, says ICMR chCOVID-19 vaccine candidates being developed by Cadila Healthcare and Bharat Biotech have completed the phase one of the study while Pune-based Serum Institute of India (SII) will begin with Phase 3 clinical trial after getting regulatory nod, says ICMR chief

COVID-19 vaccine: 3 candidates under clinical trials, Serum Institute to begin Phase 3 study soon

As a part of the expanded agreement, Serum Institute will also manufacture the antigen component of NVX‑CoV2373, Novavax’s Covid‑19 vaccine candidate.US-based Novavax's vaccine is in mid-stage trials after an early-stage trial showed it produced high levels of antibodies against the novel coronavirusAs a part of the expanded agreement, Serum Institute will also manufacture the antigen component of NVX‑CoV2373, Novavax’s Covid‑19 vaccine candidate.US-based Novavax's vaccine is in mid-stage trials after an early-stage trial showed it produced high levels of antibodies against the novel coronavirus

Novavax-Serum Institute to produce for 200 crore Covid-19 vaccine doses

Novavax announced a revision to its existing deal with the Serum Institute of India (SII) to produce 2 billion doses of its coronavirus vaccine annually.Novavax announced a revision to its existing deal with the Serum Institute of India (SII) to produce 2 billion doses of its coronavirus vaccine annually.

Vaccine Update: Biotechnology company Novavax on Tuesday announced an agreement with Serum Institute of India to manufacture and deliver Coronavirus Vaccine.Vaccine Update: Biotechnology company Novavax on Tuesday announced an agreement with Serum Institute of India to manufacture and deliver Coronavirus Vaccine.

Novavax- Serum Institute Come Together To Manufacture 'NVX‑CoV2373' COVID Vaccine; Aim To Increase Production To Over 2 Billion Doses

Access Denied

Although it is increasingly likely that one of the COVID-19 vaccines currently being tested will be approved or receive Emergency Use Authorization before the end of the year, experts are increasingly warning that widespread distribution may take a much longer time.Although it is increasingly likely that one of the COVID-19 vaccines currently being tested will be approved or receive Emergency Use Authorization before the end of the year, experts are increasingly warning that widespread distribution may take a much longer time.

Widespread Distribution of a COVID-19 Vaccine Could Take As Long as 2024 | BioSpace

Serum Institute's big announcement on coronavirus vaccine, here's when you will get first dose of COVID-19 vaccine - The Serum Institute is working with 5 international companies to develop the coronavirus vaccine.Serum Institute's big announcement on coronavirus vaccine, here's when you will get first dose of COVID-19 vaccine - The Serum Institute is working with 5 international companies to develop the coronavirus vaccine.

Serum Institute's big announcement on coronavirus vaccine, here's when you will get first dose of COVID-19 vaccine

The DCGI has also put certain conditions on SII like taking extra care during screening, providing additional information in informed consent and close monitoring for adverse events during follow-up of the study.

Serum Institute Gets DCGI Nod to Resume Clinical Trial of Oxford COVID-19 Vaccine - The Wire Science

The CEO of Serum Institute of India, Adar Poonawalla, speaking to the media has stated that it will take at least four years to make coronavirus vaccines which will be adequate for the entire world.According to Financial Times, he stated that the long wait was due to the fact that pharmaceutical companies were not ramping up their production levels quickly enough to vaccinate the global population in less time. Moreover, he added that the world will need 15 billion doses of vaccine if it is taken in two steps.The Serum Institute of India (SII) had earlier initiated human trials for its much talked about ‘Covishield’ vaccine. This vaccine is jointly developed by the University of Oxford and AstraZeneca and is considered to be one of the leading candidates to make the final cut.The first patients for Covishield’s human trials were screened and approved by Pune’s Bharati Vidyapeeth Deemed University Medical College and Hospital. It is said that the hospital aims to have up to 300 to 350 participants for this trial.Positioned to be at the forefront of India’s COVID-19 vaccine push, Serum Institute is the world’s largest vaccine manufacturer by volume, producing doses of vaccines annually for use in more than 170 countries to protect against many infectious diseases, such as polio, measles and influenza.The CEO of Serum Institute of India, Adar Poonawalla, speaking to the media has stated that it will take at least four years to make coronavirus vaccines which will be adequate for the entire world.According to Financial Times, he stated that the long wait was due to the fact that pharmaceutical companies were not ramping up their production levels quickly enough to vaccinate the global population in less time. Moreover, he added that the world will need 15 billion doses of vaccine if it is taken in two steps.The Serum Institute of India (SII) had earlier initiated human trials for its much talked about ‘Covishield’ vaccine. This vaccine is jointly developed by the University of Oxford and AstraZeneca and is considered to be one of the leading candidates to make the final cut.The first patients for Covishield’s human trials were screened and approved by Pune’s Bharati Vidyapeeth Deemed University Medical College and Hospital. It is said that the hospital aims to have up to 300 to 350 participants for this trial.Positioned to be at the forefront of India’s COVID-19 vaccine push, Serum Institute is the world’s largest vaccine manufacturer by volume, producing doses of vaccines annually for use in more than 170 countries to protect against many infectious diseases, such as polio, measles and influenza.

COVID-19 vaccine distribution could take 4 years: Adar Poonawalla | Mumbai

It's going to take four to five years until everyone gets the vaccine on this planet, Poonawalla said. He said the vaccine may require two doses, which means there will need to be upward of 15 billion doses made available.It could be another five years before the entire world is vaccinated for COVID-19, the CEO of the largest vaccine manufacturer in the world said. Adar Poonawalla, who runs the Serum Institute of India, spoke with the Financial Times and said the challenge of inoculating the...

Vaccine Maker: Vaccinating Entire World for COVID-19 May Take 5 Years | Newsmax.com

Serum Institute of India chief Adar Poonawalla has said there won't be enough vaccines available for everybody on the planet until 2024 end.  Poonawalla, CEO of the world's largest vaccine maker, said, if vaccination involved two-doses, 15 billion shots will be required to make it available for everybody. "It’s going to take four to five years until everyone gets the vaccineSerum Institute of India chief Adar Poonawalla has said there won't be enough vaccines available for everybody on the planet until 2024 end.  Poonawalla, CEO of the world's largest vaccine maker,

There won't be enough Covid-19 vaccines till 2024, says Serum Institute's Adar Poonawalla | Deccan Herald

The DCGI had on September 11 directed SII to suspend new recruitment in phase two and three clinical trials after AstraZeneca paused the clinical trials because of ''an unexplained illness'' in a participant in the study.The DCGI had on September 11 directed SII to suspend new recruitment in phase two and three clinical trials after AstraZeneca paused the clinical trials because of ''an unexplained illness'' in a participant in the study.

Coronavirus vaccine update: Serum Institute gets DCGI nod to resume clinical trial of Oxford's COVID-19 vaccine

The entire world is racing to develop a coronavirus vaccine but that doesn’t mean everyone across the globe will have access to it anytime soon.The entire world is racing to develop a coronavirus vaccine but that doesn’t mean everyone across the globe will have access to it anytime soon.

Experts warn it might take up to four years to supply COVID-19 vaccine globally

At a time when the whole world is eagerly awaiting good news to fight the Coronavirus, Serum Institute of India CEO Adar Poonawalla expressed doubt thatAt a time when the whole world is eagerly awaiting good news to fight the Coronavirus, Serum Institute of India CEO Adar Poonawalla expressed doubt that

Vaccine Might Not Be Available To All Till 2024: Serum Institute CEO - Gulte

The Serum Institute of India (SII) is all set to restart its phase two and three clinical trials for the COVID-19 vaccine after getting the nod from the Drugs Controller General of India (DCGI).The Serum Institute of India (SII) is all set to restart its phase two and three clinical trials for the COVID-19 vaccine after getting the nod from the Drugs Controller General of India (DCGI).

Serum Institute of India gets DCGI permission to restart phase 2, 3 trials of coronavirus COVID-19 vaccine | India News | Zee News

As millions across the nation wait for a coronavirus vaccine to be administered, the chief executive of Serum Institute of India, the world’s biggest vaccine producer, suggested that once developed, a COVID-19 vaccine may not fully reach the population until 2024. The date is because [...]As millions across the nation wait for a coronavirus vaccine to be administered, the chief [...]

Coronavirus Vaccine Won't Be Available to Everyone Until 2024, CEO of World's Biggest Producer Says

Serum Institute, which is in Pune, has partnered with five international pharmaceutical companies, including AstraZeneca and Novavax, to develop a vaccine and pledged to manufacture one billion doses, out of which it has promised 50% to India.Serum Institute, which is in Pune, has partnered with five international pharmaceutical companies, including AstraZeneca and Novavax, to develop a vaccine and pledged to manufacture one billion doses, out of which it has promised 50% to India.

Coronavirus Vaccine Won’t Be Available to Everyone Before End of 2024, Says Serum Institute Chief

Even with manufacturing ramped up significantly, there won't be enough COVID vaccines available for the entire globe until the end of 2024.Even with manufacturing ramped up significantly, there won't be enough COVID vaccines available for the entire globe until the end of 2024.

There Won’t Be Enough COVID Vaccines for Everybody Until 2024, Warn Vaccine Makers

Even with manufacturing ramped up significantly, there won't be enough COVID vaccines available for the entire globe until the end of 2024.Even with manufacturing ramped up significantly, there won't be enough COVID vaccines available for the entire globe until the end of 2024.

There Won't Be Enough COVID Vaccines for Everybody Until 2024, Warn Vaccine Makers

Maybe the wait is worth it! Click here to see why a viable coronavirus vaccine might not come fast.Maybe the wait is worth it! Click here to see why a viable coronavirus vaccine might not come fast.

Coronavirus Vaccine - No Rest From COVID-19 Until 2024? | IE

News, analysis and comment from the Financial Times, the worldʼs leading global business publication

Subscribe to read | Financial Times

The world's biggest vaccine producer, the Serum Institute of India, has warned it will take until at least 2024 to make enough vaccines to go around.The world's biggest vaccine producer, the Serum Institute of India, has warned it will take until at least 2024 to make enough vaccines to go around.

COVID-19 vaccine won't reach everyone until 2024: Serum Institute of India - Business Insider

corona vaccine available in india - Covid-19 vaccine, Serum Institute's big announcement on coronavirus vaccine will not be available for everybody in the world to be immunised until the end of 2024.In a big blow to the expectations regarding the covid-19 vaccine, the Serum Institute of India has said adequate coronavirus vaccine will not be available for everybody in the world to be immunised until the end of 2024. The chief executive of the world’s largest manufacturer of vaccines, Adar Poonawalla, has said dampened the hopes of a COVID-19 vaccine by year-end in an interview with the Financial Times. He said that pharma firms were not ramping up production capacity swiftly to be able to innoculate the world population in less duration.

Coronavirus vaccine won’t be available to everyone before 2024 end: India's Serum Institute chief, India News News | wionews.com

The chief executive of the world’s largest vaccine producer is cautioning that the world’s population may not be fully vaccinated against the coronavirus until at least the end of 2024, he said in an interview with the Financial Times.The chief executive of the world’s largest vaccine producer is cautioning that the world’s population may not be fully vaccinated against the coronavirus until at least the end of 2024, he said in an interview with the Financial Times.

Vaccine producer says it could take ‘four to five years’ for the world to receive a COVID-19 dose - The Boston Globe

Twenty-five MPs tested positive for the coronavirus. Twenty-five MPs tested positive for the coronavirus.

Coronavirus LIVE: Won’t be enough vaccines for whole world for 4 to 5 years, says Adar Poonawalla

Twenty-five MPs tested positive for the coronavirus. Twenty-five MPs tested positive for the coronavirus.

Coronavirus LIVE: Won’t be enough vaccines for whole world for 4 to 5 years, says Adar Poonawalla